SRI Biosciences delivers next-generation drugs, diagnostics and devices to solve unmet medical needs. We work with partners to develop transformative approaches and platforms for the toughest therapeutic problems.
“Our innovation strategies are built on more than 50 years of drug development and discovery experience. We’ve refined our ability to repeat biomedical discovery and catalyze innovation into new products.”
Ian M. Colrain
President, Biosciences Division
Some of our innovators
Our latest
more +
COVID tied to a profound impact on children’s sleep
SRI’s Dr. Orsolya Kiss comments on findings from the ongoing ABCD study
Teen screen time goes hand in hand with wacky bedtimes during the pandemic
SRI’s Dr. Kiss says urgent need to help families to formulate age-appropriate media use plans
Children spending more time on screens, going to bed later during pandemic
Data highlights the need to promote children’s balanced and informed use of digital technology for better sleep and behavior
Areas of expertise
Collaborative research
Neuroimaging and electrophysiological research
Sleep device design and validation
Adolescent development
Translational approaches using in vivo MRI
Translational neuroscience
Drug discovery
Technology platforms for new approaches to drug discovery
Small molecule and biologic therapies
AI-driven drug design
Target validation and assay development and screening
Lead identification, optimization and synthesis
Diagnostics and devices
Fiber-optic Array Scanning Technology (FAST) rare cell detection
High-speed hyperspectral imaging
Wearable sleep technology
Diagnostic biomarker discovery
SynFini: automated chemistry design and synthesis
Chemical and biological sensing solutions
Product development services
Pharmacology, efficacy and predictive ADMET
Safety, drug metabolism and pharmacokinetics
Formulation design
Clinical drug product manufacturing
Clinical trials
Platforms
SRI Biosciences’ highly specialized platforms marry the advantages of our cutting-edge research with our flexible biotech business model. Partner with us to leverage our rigorous early discovery and development to customize your specific applications.
FOX Three Molecular Guidance System™
Cell-selective, intracellular delivery of macromolecular therapeutics: Deliver essentially any cargo to selected cell types, and internalize into those cells to targeted subcellular locations.
SynFini™
Suite of automated tools leverages AI to recreate and scale literature-reported synthesis procedures. Solutions focus on key areas of route design, reaction screening and optimization (RSO), and multi-step synthesis development.
Techneins™
Non-natural polymers as synthetic affinity reagents and novel therapeutics
Synthetic Lethals
AI-guided precision cancer therapy platform provides a new approach to finding targeted therapies for previously “undruggable mutations.”
Fields of research
We work with commercial, government and academic clients and partners to help save and improve lives worldwide. Our leading-edge R&D is concentrated in the following areas to solve important problems in prevention, diagnosis and treatment.
- Human sleep
- Point of care diagnostics
- Aging and neurodegenerative diseases
- Neuroimaging and electrophysiological research
- Blood brain barrier transport
- Toxicology and safety
- Homeland security/national defense
- Immuno-oncology
- Intracellular biologic therapies
- Medical countermeasures
- Formulation design
- Biomarker discovery, development, validation
Collaborative models
SRI Biosciences takes on the toughest biomedical challenges with transformative approaches and platforms. We partner closely with clients in areas including:
- Co-development/licensing
- Federal subcontract teaming
- Grant teaming
- Incubator space and services
- Joint business partnerships
- Regulatory support
- Technology platforms
“There are many talented researchers from various disciplines at SRI. This creates an exciting environment and fertile ground for cutting edge research thanks to the cooperation of different teams. This highly effective collaboration allows SRI to invent and develop unique and novel products and technologies.”
Michal Avital-Shmilovici
Research Scientist, Biosciences Division
